Inclusion Criteria:
1. Male or female participants aged ≥6 and \<12 years at the time of informed consent.
2. Refractive status meets the following conditions:
a) Myopia of 0.5 D (diopters) to 4.00 D (inclusive) in both eyes; B) Astigmatism ≤1.50 D in both eyes; c) Anisometropia ≤1.5 D;
3. Intraocular pressure ≤21 mmHg;
4. The best corrected distance visual acuity of both eyes of logMAR 0 or better;
Exclusion Criteria:
1. Allergy to the investigational drug or any of its components.
2. Any abnormality of the refractive system in either eye, including but not limited to keratoconus, lenticonus, or spherophakia.
3. Systemic conditions that may affect refractive development or predispose to high myopia, such as Down syndrome, Marfan syndrome, retinopathy of prematurity, or neonatal hypoxic-ischemic encephalopathy.
4. Any other ocular abnormality or disease affecting vision in either eye, including ptosis, congenital corneal abnormalities, corneal leukoma, congenital lens abnormalities, cataract, macular lesions, choroidal lesions, severe vitreous opacity, or retinal lesions.
5. History of glaucoma and/or shallow anterior chamber in either eye.
6. History or current presence of significant strabismus, amblyopia, or nystagmus.
7. Prior eyelid surgery, strabismus surgery, intraocular surgery, or refractive surgery.
8. Systemic or local use of medications that may affect efficacy evaluation within 3 months prior to screening, including anticholinergics (e.g., atropine, pirenzepine), cholinergics (e.g., pilocarpine), or drugs affecting pupil size or accommodation (e.g., Belladonna tablets, morphine, sedative-hypnotics). Exception: non-atropine mydriatics used solely for dilated eye examinations, provided they are not continuous, regular, or long-term use.
9. Use of myopia control treatments within 1 month prior to screening, including atropine or other antimuscarinic agents, bifocal/progressive/multifocal contact lenses or spectacles, orthokeratology lenses, or rigid gas permeable contact lenses for myopia reduction.
10. History or current presence of systemic diseases, including immune system disorders, central nervous system disorders, asthma, diabetes, severe cardiopulmonary dysfunction, or severe hepatic or renal dysfunction.
11. Clear family history of high myopia.
12. Participation in another interventional clinical trial within 3 months prior to randomization.
13. Any other condition that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial.
